Theravance Biopharma TBPH Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's accounts payable?
- Theravance Biopharma (TBPH) reported accounts payable of $1.1M in Q1 2026.
- How has Theravance Biopharma's accounts payable changed year-over-year?
- Theravance Biopharma's accounts payable decreased by 54.3% year-over-year, from $2.41M to $1.1M.
- What is the long-term trend for Theravance Biopharma's accounts payable?
- Over 5 years (2020 to 2025), Theravance Biopharma's accounts payable has grown at a -17.6% compound annual growth rate (CAGR), from $6.78M to $2.57M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.